Clinical trials · Dallas–Fort Worth, TX
Metastatic Colorectal Cancer clinical trials in Dallas–Fort Worth
We’re tracking 48 recruiting metastatic colorectal cancer studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Dallas, TexasAges 18 years+ - NCT05863195RecruitingPhase 3
Testing a liver pump with standard chemo for colorectal cancer that spread to the liver
This trial tests whether adding a special chemotherapy pump implanted in your liver (hepatic arterial infusion) to standard chemotherapy works better than standard chemotherapy alone for people whose colorectal cancer has spread only to the liver and cannot be removed by surgery. The pump delivers high doses of chemo directly to the liver to shrink tumors and possibly control the disease longer.
Dallas, TexasAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Dallas, TexasAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Dallas, TexasAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Dallas, TexasAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Dallas, TexasAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Dallas, TexasAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Dallas, TexasAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Dallas, TexasAges 18 years+ - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Dallas, TexasAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Dallas, TexasAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Dallas, TexasAges 12 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Dallas, TexasAges 18 years+ - NCT05394103RecruitingPhase 1/Phase 2
Testing a targeted pill for hard-to-treat solid tumors
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Dallas, TexasAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Dallas, TexasAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Dallas, TexasAges 18–99 - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Dallas, TexasAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Dallas, TexasAges 18 years+ - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Dallas, TexasAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Dallas, TexasAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Dallas, TexasAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Dallas, TexasAges 18 years+
Hear when a new Metastatic Colorectal Cancer trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Metastatic Colorectal Cancer trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting metastatic colorectal cancer studies listed above.
- University of Texas Southwestern Medical Center · 7 studies
- Mary Crowley Cancer Research · 5 studies
- Texas Oncology · 3 studies
- UT Southwestern Medical Center · 3 studies
- Texas Oncology - DFW · 2 studies
- 89bio Clinical Study Site
- Baylor University Medical Center
- Clinical Study Site
What taking part in a metastatic colorectal cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic colorectal cancer studies in Texas.
Common questions
- Are there metastatic colorectal cancer clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 48 recruiting metastatic colorectal cancer studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic colorectal cancer study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic colorectal cancer studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.